Novartis India deal closes 2026; ChrysCapital control

What changed at Novartis India on July 29, 2026

Novartis India Limited reported that a major ownership and governance transition was completed on July 29, 2026, alongside a broad reconstitution of its Board. The change followed ChrysCapital entities acquiring control of the company and the conclusion of the underlying share purchase transaction. The company also recorded that the Share Purchase transaction and the Open Offer were concluded on the same date, marking the formal end of the process.

The development is significant for shareholders because it changes who controls the listed Indian entity, how it is classified in shareholding disclosures, and who oversees board-level decisions. As part of the change, Novartis AG was reclassified from the promoter category to the public category. Control was stated to have been acquired by WaveRise Investments Limited and ChrysCapital Fund X.

The share sale that triggered the control change

At its 245th Board meeting held on July 29, 2026, the Board noted completion of the sale of 17,450,680 equity shares from Novartis AG to three acquirers: WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The acquirers were collectively referred to as “CC” in the board context.

The transaction was executed under a Share Purchase Agreement dated February 19, 2026. The company identified July 29, 2026 as the Closing Date. The same date also marked the completion of the open offer process referenced in the company’s governance notes.

Open Offer milestones referenced by the Board

In the context of the board reconstitution, the resigning directors referenced completion of the Open Offer on July 7, 2026, and the resulting change in control as the reason for stepping down. The company separately stated that both the share purchase transaction and the Open Offer were concluded on July 29, 2026.

Taken together, the disclosures frame July 29, 2026 as the date when control transition and governance changes became effective, while also acknowledging July 7, 2026 as a key open offer milestone cited in resignation letters.

Promoter to public reclassification of Novartis AG

Novartis AG was reclassified from the “promoter” category to the “public” category following the change in control. Such a reclassification matters for investors tracking promoter holdings, promoter-related disclosures, and changes in control under Indian listing and takeover frameworks.

The company’s board documentation also recorded that WaveRise Investments Limited and ChrysCapital Fund X acquired control. This is an important distinction for public market disclosures because the “promoter” label carries different reporting expectations and is often watched closely by minority shareholders.

Board overhaul: six new directors appointed

Effective July 29, 2026, the Board appointed six new directors:

• Mr. Ashok Bhatia
• Mr. Kshitij Sheth
• Dr. Jagriti Gupta
• Mr. Ramesh Ramadurai
• Mr. Shashank Sinha
• Ms. Suchita Sharma

The appointments were disclosed as part of the board’s reconstitution following the ownership change. The effective date aligns with the company’s Closing Date for the acquisition and the stated completion of the wider transaction process.

Six outgoing directors resign, including Chairperson and CFO

Six directors tendered their resignations with effect from July 29, 2026, following the change in control. The resignation letters cited completion of the Open Offer on July 7, 2026 and the resulting change in control as the primary reasons for stepping down. The company also stated that each resigning director stepped down from their respective board committee memberships at the same time.

The outgoing directors and their designations prior to resignation were listed by the company as follows.

The independent directors confirmed there were no material reasons beyond those stated in their resignation letters.

Key transaction facts investors can pin down

The company’s disclosures provide a clear set of dated events and identifiers that investors commonly use to track corporate actions and filings across exchanges.

Market snapshot included in the data feed

The provided market data includes price snapshots showing declines of 2.30 percent and 2.72 percent at levels of 1438.50 and 1434.90, respectively, timestamped “Jun 25, 16:01”. The data does not explicitly link this move to the July 29, 2026 control change, and the timestamps appear earlier than the closing date.

Still, such information is relevant for context because ownership transitions and board changes are often accompanied by heightened attention on trading activity, disclosures, and shareholding patterns. Investors typically watch for subsequent filings that clarify post-transaction shareholding distribution and any further governance changes.

Why this change matters for governance and disclosures

A control change typically reshapes board oversight, committee composition, and how strategic decisions are reviewed. In this case, the company recorded the simultaneous appointment of six new directors and resignation of six outgoing directors effective July 29, 2026, indicating a full turnover aligned with the new controlling shareholders.

The promoter reclassification of Novartis AG to the public category also changes how the company’s shareholding is presented in filings. For public market participants, this can affect how they interpret control, influence, and related reporting lines in quarterly and event-based disclosures.

What to watch next

Based on the company’s stated timeline, the immediate next items for shareholders are typically follow-on exchange disclosures that reflect the updated board composition, committee memberships, and revised shareholding classification. Investors may also track any additional filings connected to the completion of the SPA and open offer process.

The company’s registered office details and investor contact information were provided in the material, which can help shareholders route queries to the company and its registrar as needed.

Conclusion

Novartis India’s July 29, 2026 disclosures mark the completion of a control change to ChrysCapital entities, the promoter reclassification of Novartis AG to public, and a board reconstitution with six appointments and six resignations. The closing date, the SPA date, and the open offer milestone cited in resignations provide a clear framework for tracking subsequent filings and governance updates.